US Patent

US11203593 — Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate

Method of Use · Assigned to Adverio Pharma GmbH · Expires 2034-02-18 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects various forms of the drug substance methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate.

USPTO Abstract

This present invention relates to forms of methyl {4.6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3.4-b]pyridino-3-yl]pyrimidino-5-yl}methylcarbamate comprising its Modification I. Modification II. mono-DMSO solvate. sesqui-DMSO solvate and Â¼-ethyl acetate solvate.

Drugs covered by this patent

Adempas (RIOCIGUAT) · Bayer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2834`	—	Adempas
`U-2834`	—	Adempas
`U-2834`	—	Adempas
`U-2834`	—	Adempas
`U-2834`	—	Adempas

Patent Metadata

Patent number: US11203593
Jurisdiction: US
Classification: Method of Use
Expires: 2034-02-18
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Adverio Pharma GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.